Binding agents that specifically bind the extracellular domain of human TIGIT and methods of use are disclosed. The binding agents may comprise a soluble poliovirus receptor (PVR) variant with one or more amino acid substitutions as compared to wild-type PVR. Binding agents may specifically bind the extracellular domain of human TIGIT and do not bind or bind weakly to the extracellular domain of human CD226, which can be used in the methods for the treatment of diseases such as cancer.Linvention concerne des agents de liaison qui modulent la réponse immunitaire. Les agents de liaison peuvent comprendre des récepteurs solubles, des polypeptides et/ou des anticorps. Linvention concerne également des procédés dutilisation des agents de liaison pour le traitement de maladies telles que le cancer.
